Kidney Disease
Dimerix Bioscience Pty Limited focuses on focal segmental glomerulosclerosis, a severe form of glomerular disease associated with progressive loss of kidney function.
- Focal segmental glomerulosclerosis
- Proteinuria
- Estimated glomerular filtration rate
The sponsor’s active clinical work is centred on adult patients with persistent renal impairment and the preservation of kidney function in a nephrology setting.
Nephrology Outcomes
Its research interest includes clinical endpoints used in renal medicine, particularly measures of urinary protein loss and long-term changes in eGFR.
- Urine protein-to-creatinine ratio
- Renal function decline
- Chronic kidney disease
This places emphasis on disease monitoring and functional kidney outcomes in patients with progressive proteinuric kidney disorders.
Renin-Angiotensin System–Related Care
The sponsor’s clinical activity also involves patients receiving an angiotensin receptor blocker, reflecting interest in treatments used to support blood pressure control and reduce glomerular stress.
- Angiotensin receptor blockers
- Supportive renal therapy
- Proteinuria management
Its therapeutic landscape sits within adjunctive care for glomerular pathology and the management of persistent urinary protein loss.
Long-Term Safety and Tolerability
Dimerix Bioscience Pty Limited includes ongoing evaluation of long-term safety and tolerability in patients with FSGS, with attention to sustained treatment use in a chronic kidney condition.
- Chronic treatment monitoring
- Adult nephrology
- Persistent renal disease
The clinical focus remains on adult populations with progressive renal disease requiring extended observation of kidney-related outcomes.
